DexCom Capital Stock vs Total Current Assets Analysis
DXCM Stock | USD 125.17 0.71 0.56% |
DexCom financial indicator trend analysis is much more than just examining DexCom Inc latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether DexCom Inc is a good investment. Please check the relationship between DexCom Capital Stock and its Total Current Assets accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
Capital Stock vs Total Current Assets
Capital Stock vs Total Current Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of DexCom Inc Capital Stock account and Total Current Assets. At this time, the significance of the direction appears to have strong relationship.
The correlation between DexCom's Capital Stock and Total Current Assets is 0.75. Overlapping area represents the amount of variation of Capital Stock that can explain the historical movement of Total Current Assets in the same time period over historical financial statements of DexCom Inc, assuming nothing else is changed. The correlation between historical values of DexCom's Capital Stock and Total Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Stock of DexCom Inc are associated (or correlated) with its Total Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Assets has no effect on the direction of Capital Stock i.e., DexCom's Capital Stock and Total Current Assets go up and down completely randomly.
Correlation Coefficient | 0.75 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Capital Stock
The total amount of a company’s capital funded by shareholders through the issue and subscription of shares.Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Most indicators from DexCom's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into DexCom Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. At this time, DexCom's Selling General Administrative is very stable compared to the past year. As of the 2nd of May 2024, Tax Provision is likely to grow to about 177.3 M, while Issuance Of Capital Stock is likely to drop about 19.7 M.
DexCom fundamental ratios Correlations
Click cells to compare fundamentals
DexCom Account Relationship Matchups
DexCom fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 2.4B | 4.3B | 4.9B | 5.4B | 6.3B | 6.6B | |
Total Stockholder Equity | 882.6M | 1.8B | 2.3B | 2.1B | 2.1B | 2.2B | |
Net Debt | 699.5M | 1.0B | 769.2M | 1.4B | 2.0B | 2.1B | |
Cash | 446.2M | 817.6M | 1.1B | 642.3M | 566.3M | 594.6M | |
Cash And Short Term Investments | 1.5B | 2.7B | 2.7B | 2.5B | 2.7B | 2.9B | |
Common Stock Shares Outstanding | 369.2M | 390M | 428.8M | 427.5M | 425.5M | 246.4M | |
Liabilities And Stockholders Equity | 2.4B | 4.3B | 4.9B | 5.4B | 6.3B | 6.6B | |
Total Current Assets | 2.0B | 3.4B | 3.7B | 3.7B | 4.4B | 4.6B | |
Other Current Liab | 88.5M | 432.1M | 125.2M | 134.3M | 1.2B | 1.3B | |
Total Current Liabilities | 360.2M | 614.1M | 720.8M | 1.8B | 1.6B | 1.6B | |
Property Plant And Equipment Net | 392.8M | 608.6M | 889.9M | 1.1B | 1.2B | 1.2B | |
Retained Earnings | (695.7M) | (202.1M) | (47.4M) | 479.9M | 1.0B | 1.1B | |
Accounts Payable | 256.4M | 163.3M | 573M | 901.8M | 276.4M | 290.2M | |
Non Current Assets Total | 425.6M | 865.7M | 1.2B | 1.7B | 1.8B | 1.9B | |
Non Currrent Assets Other | 14.2M | 21.4M | (4.5M) | 28.1M | 36.5M | 38.3M | |
Other Assets | 14.2M | 237.8M | 220.8M | 369.3M | 424.7M | 445.9M | |
Non Current Liabilities Total | 1.2B | 1.8B | 1.9B | 1.4B | 2.6B | 2.8B | |
Other Current Assets | 30M | 53.9M | 81.6M | 192.6M | 49.3M | 25.1M | |
Other Stockholder Equity | 1.6B | 2.0B | 2.3B | 1.7B | 1.1B | 1.1B | |
Total Liab | 1.5B | 2.5B | 2.6B | 3.3B | 4.2B | 4.4B | |
Property Plant And Equipment Gross | 392.8M | 608.6M | 801.8M | 1.1B | 1.7B | 1.8B | |
Accumulated Other Comprehensive Income | 2.3M | 3.2M | 500K | (11.6M) | (16.7M) | (15.9M) | |
Property Plant Equipment | 321.3M | 515.3M | 889.9M | 1.1B | 1.3B | 1.4B | |
Other Liab | 5.7M | 80.9M | 90M | 68.7M | 79.0M | 83.0M | |
Short Term Investments | 1.1B | 1.9B | 1.7B | 1.8B | 2.2B | 2.3B | |
Short Long Term Debt Total | 1.1B | 1.8B | 1.8B | 2.1B | 2.6B | 2.7B | |
Long Term Debt | 1.1B | 1.7B | 1.7B | 1.2B | 2.4B | 2.6B | |
Net Receivables | 286.3M | 428.5M | 514.3M | 713.3M | 987.5M | 1.0B | |
Inventory | 119.8M | 234.7M | 357.3M | 306.7M | 559.6M | 587.6M | |
Short Term Debt | 13.6M | 16.5M | 20.5M | 793.1M | 21.1M | 20.0M | |
Current Deferred Revenue | 1.7M | 2.2M | 2.1M | 10.1M | 18.4M | 19.3M | |
Net Tangible Assets | 864M | 1.8B | 2.2B | 2.1B | 2.5B | 2.6B | |
Good Will | 18.6M | 19.3M | 26.5M | 25.7M | 25.2M | 14.4M | |
Retained Earnings Total Equity | (695.7M) | (202.1M) | (47.4M) | 479.9M | 551.9M | 579.5M | |
Capital Surpluse | 1.7B | 2.1B | 2.5B | 2.3B | 2.6B | 1.5B |
Pair Trading with DexCom
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DexCom position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DexCom will appreciate offsetting losses from the drop in the long position's value.Moving together with DexCom Stock
0.63 | CI | Cigna Corp Earnings Call Today | PairCorr |
Moving against DexCom Stock
0.83 | ALHC | Alignment Healthcare LLC | PairCorr |
0.72 | UNH | UnitedHealth Group Financial Report 12th of July 2024 | PairCorr |
0.7 | CLOV | Clover Health Investments Financial Report 14th of May 2024 | PairCorr |
0.66 | ZJYL | JIN MEDICAL INTERNATIONAL | PairCorr |
0.65 | HUM | Humana Inc Financial Report 7th of August 2024 | PairCorr |
The ability to find closely correlated positions to DexCom could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DexCom when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DexCom - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DexCom Inc to buy it.
The correlation of DexCom is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DexCom moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DexCom Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DexCom can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the DexCom Inc information on this page should be used as a complementary analysis to other DexCom's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for DexCom Stock analysis
When running DexCom's price analysis, check to measure DexCom's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DexCom is operating at the current time. Most of DexCom's value examination focuses on studying past and present price action to predict the probability of DexCom's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DexCom's price. Additionally, you may evaluate how the addition of DexCom to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is DexCom's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.987 | Earnings Share 1.53 | Revenue Per Share 9.827 | Quarterly Revenue Growth 0.242 | Return On Assets 0.0679 |
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.